April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Three-Year Follow Up of a Randomized Trial Comparing Focal/Grid Photocoagulation and Intravitreal Triamcinolone for Diabetic Macular Edema
Author Affiliations & Notes
  • M. S. Ip
    Ophthalmology, Univ of Wisconsin-Madison, Madison, Wisconsin
  • R. W. Beck
    Jaeb Center for Health Research, Tampa, Florida
  • A. R. Edwards
    Ophthalmology, Univ of Wisconsin-Madison, Madison, Wisconsin
  • N. M. Bressler
    Ophthalmology, Univ of Wisconsin-Madison, Madison, Wisconsin
  • Footnotes
    Commercial Relationships  M.S. Ip, None; R.W. Beck, None; A.R. Edwards, None; N.M. Bressler, None.
  • Footnotes
    Support  Supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1675. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. S. Ip, R. W. Beck, A. R. Edwards, N. M. Bressler, For the Diabetic Retinopathy Clinical Research Network; Three-Year Follow Up of a Randomized Trial Comparing Focal/Grid Photocoagulation and Intravitreal Triamcinolone for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1675.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report 3-year follow up of a randomized trial evaluating 1 mg and 4 mg doses of preservative-free intravitreal triamcinolone in comparison with focal/grid photocoagulation for the treatment of diabetic macular edema (DME).

Methods: : Eyes with DME and visual acuity 20/40 to 20/320 were randomly assigned to focal/grid photocoagulation, 1 mg triamcinolone, or 4 mg triamcinolone. At the conclusion of the trial, 3-year follow up was available for 306 eyes.

Results: : Between two and three years of follow up, more eyes in all three treatment groups improved than worsened with respect to visual acuity and OCT central subfield thickness. Mean change in the visual acuity letter score from baseline to 3 years was +5 in the laser group and 0 in each triamcinolone group. Mean change in the central subfield from baseline to 3 years was -175 microns in the laser group, -124 microns in the 1 mg triamcinolone group and -126 microns in the 4 mg triamcinolone group. The cumulative probability of cataract surgery by three years was 31%, 46%, and 83% in the laser, 1 mg triamcinolone, and 4 mg triamcinolone groups, respectively. Intraocular pressure increased ≥10 mm Hg at any visit in 4%, 18%, and 33%, respectively.

Clinical Trial: : www.clinicaltrials.gov NCT00367133

Keywords: diabetic retinopathy • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×